|
Mark McDade has served as Lead Director of our board of Directors since January 2007 and has been a memeber of the board since April 2005. Since November 2002, Mr. McDade has been Chief Executive Officer and a Director of PDL BioPharma, Inc. (Nasdaq: PDLI). From December 2000 until November 2002, he served as Chief Executive Officer of Signature BioScience, Inc. Prior to Signature, he was a co-founder and director of Corixa Corporation (Nasdaq: CRXA). He served as Chief Operating Officer at Corixa from September 1994 through December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000. Before Corixa, he was Chief Operating Officer of Boehringer Mannheim-Therapeutics. Prior to Boehringer Mannheim-Therapeutics, he served in several positions at Sandoz Ltd., which included business development, product management and general management responsibilities. Mr. McDade currently serves on the board of directors of Valentis, Inc. and LigoCyte Pharmaceuticals, Inc. Mr. McDade received a B.A. in History from Dartmouth College and an M.B.A. from Harvard Business School. | 